CoChat
Sign Up
Cited by 189

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The intrinsic substrate specificity of the human tyrosine kinome

Yaron-Barir, Tomer M., Joughin, Brian A., Huntsman, Emily M., Kerelsky, Alexander, Cizin, Daniel M., Cohen, Benjamin M., Regev, Amit, Song, Junho, Vasan, Neil, Lin, Ting-Yu, Orozco, Jose M., Schoenherr, Christina, Sagum, Cari, Bedford, Mark T., Wynn, R. Max, Tso, Shih-Chia, Chuang, David T., Li, Lei, Li, Shawn S.-C., Creixell, Pau, Krismer, Konstantin, Takegami, Mina, Lee, Harin, Zhang, Bin, Lu, Jingyi, Cossentino, Ian, Landry, Sean D., Uduman, Mohamed, Blenis, John, Elemento, Olivier, Frame, Margaret C., Hornbeck, Peter V., Cantley, Lewis C., Turk, Benjamin E., Yaffe, Michael B., Johnson, Jared L.·2024·Nature
DOI 10.1038/s41586-024-07407-yPMC PMC11136658
Open this paper in CoChat — free account

Abstract

Phosphorylation of proteins on tyrosine (Tyr) residues evolved in metazoan organisms as a mechanism of coordinating tissue growth 1. Multicellular eukaryotes typically have more than 50 distinct protein Tyr kinases that catalyse the phosphorylation of thousands of Tyr residues throughout the proteome 1–3. How a given Tyr kinase can phosphorylate a specific subset of proteins at unique Tyr sites is only partially understood 4–7. Here we used combinatorial peptide arrays to profile the substrate sequence specificity of all human Tyr kinases. Globally, the Tyr kinases demonstrate considerable diversity in optimal patterns of residues surrounding the site of phosphorylation, revealing the functional organization of the human Tyr kinome by substrate motif preference. Using this information, Tyr kinases that are most compatible with phosphorylating any Tyr site can be identified. Analysis of mass spectrometry phosphoproteomic datasets using this compendium of kinase specificities accurately identifies specific Tyr kinases that are dysregulated in cells after stimulation with growth factors, treatment with anti-cancer drugs or expression of oncogenic variants. Furthermore, the topology of known Tyr signalling networks naturally emerged from a comparison of the sequence specificities of the Tyr kinases and the SH2 phosphotyrosine (pTyr)-binding domains. Finally we show that the intrinsic substrate specificity of Tyr kinases has remained fundamentally unchanged from worms to humans, suggesting that the fidelity between Tyr kinases and their protein substrate sequences has been maintained across hundreds of millions of years of evolution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-024-07407-y

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 74

  1. Hunter, T. The genesis of tyrosine phosphorylation. Cold Spring Harb. Perspect. Biol. 6, a020644 (2014). · DOI
  2. Hornbeck, P. V. et al. 15 years of PhosphoSitePlus®: integrating post-translationally modified sites, disease variants and isoforms. Nucleic Acids Res. 47, D433–D441 (2019). · DOI
  3. Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–1134 (2010). · DOI · Paper page
  4. Shah, N. H., Amacher, J. F., Nocka, L. M. & Kuriyan, J. The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases. Crit. Rev. Biochem. Mol. Biol. 53, 535–563 (2018). · DOI
  5. Shah, N. H. et al. An electrostatic selection mechanism controls sequential kinase signaling downstream of the T cell receptor. eLife 5, e20105 (2016). · DOI
  6. Li, A., Voleti, R., Lee, M., Gagoski, D. & Shah, N. H. High-throughput profiling of sequence recognition by tyrosine kinases and SH2 domains using bacterial peptide display. eLife 12, e82345 (2023). · DOI
  7. Rush, J. et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23, 94–101 (2005). · DOI
  8. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203 (2007). · DOI · Paper page
  9. Gerritsen, J. S. & White, F. M. Phosphoproteomics: a valuable tool for uncovering molecular signaling in cancer cells. Expert Rev. Proteom. 18, 661–674 (2021). · DOI
  10. Eckhart, W., Hutchinson, M. A. & Hunter, T. An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates. Cell 18, 925–933 (1979). · DOI
  11. Hunter, T. & Sefton, B. M. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl Acad. Sci. USA 77, 1311–1315 (1980). · DOI
  12. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001). · DOI
  13. Cohen, P., Cross, D. & Jänne, P. A. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat. Rev. Drug Discov. 20, 551–569 (2021). · DOI
  14. Trenker, R. & Jura, N. Receptor tyrosine kinase activation: from the ligand perspective. Curr. Opin. Cell Biol. 63, 174–185 (2020). · DOI
  15. Sadowski, I., Stone, J. C. & Pawson, T. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol. Cell. Biol. 6, 4396–4408 (1986). · DOI
  16. Yaffe, M. B. Phosphotyrosine-binding domains in signal transduction. Nat. Rev. Mol. Cell Biol. 3, 177–186 (2002). · DOI
  17. Lim, W. A. & Pawson, T. Phosphotyrosine signaling: evolving a new cellular communication system. Cell 142, 661–667 (2010). · DOI
  18. Needham, E. J., Parker, B. L., Burykin, T., James, D. E. & Humphrey, S. J. Illuminating the dark phosphoproteome. Science Signal. 12, eaau8645 (2019). · DOI
  19. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002). · DOI · Paper page
  20. Sugiyama, N., Imamura, H. & Ishihama, Y. Large-scale discovery of substrates of the human kinome. Sci. Rep. 9, 10503 (2019). · DOI
  21. Van de Kooij, B. et al. Comprehensive substrate specificity profiling of the human Nek kinome reveals unexpected signaling outputs. eLife 8, e44635 (2019). · DOI
  22. Lagoutte, E. et al. LIMK regulates tumor-cell invasion and matrix degradation through tyrosine phosphorylation of MT1-MMP. Sci. Rep. 6, 24925 (2016). · DOI
  23. Kettenbach, A. N. et al. Rapid determination of multiple linear kinase substrate motifs by mass spectrometry. Chem. Biol. 19, 608–618 (2012). · DOI
  24. Mayer, B. J. Perspective: dynamics of receptor tyrosine kinase signaling complexes. FEBS Lett. 586, 2575–2579 (2012). · DOI
  25. Yeung, W. et al. Evolution of functional diversity in the holozoan tyrosine kinome. Mol. Biol. Evol. 38, 5625–5639 (2021). · DOI
  26. Sieg, D. J. et al. Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK− cell migration. EMBO J. 17, 5933–5947 (1998). · DOI
  27. Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D. & Frame, M. C. Targeting FAK in anticancer combination therapies. Nat. Rev. Cancer 21, 313–324 (2021). · DOI
  28. Philips, R. L. et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell 185, 3857–3876 (2022). · DOI
  29. Begley, M. J. et al. EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src. Nat. Struct. Mol. Biol. 22, 983–990 (2015). · DOI
  30. Davis, T. L. et al. Structural recognition of an optimized substrate for the ephrin family of receptor tyrosine kinases. FEBS J. 276, 4395–4404 (2009). · DOI
  31. Courtney, A. H., Lo, W.-L. & Weiss, A. TCR signaling: mechanisms of initiation and propagation. Trends Biochem. Sci 43, 108–123 (2018). · DOI
  32. Yaffe, M. B. et al. A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nat. Biotechnol. 19, 348–353 (2001). · DOI · Paper page
  33. Yaron, T. M. et al. Host protein kinases required for SARS-CoV-2 nucleocapsid phosphorylation and viral replication. Sci. Signal. 15, eabm0808 (2022). · DOI
  34. Lew, E. D., Furdui, C. M., Anderson, K. S. & Schlessinger, J. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci. Signal. 2, ra6 (2009).
  35. Batth, T. S. et al. Large-scale phosphoproteomics reveals Shp-2 phosphatase-dependent regulators of Pdgf receptor signaling. Cell Rep. 22, 2784–2796 (2018). · DOI
  36. Budayeva, H. G. et al. Phosphoproteome profiling of the receptor tyrosine kinase MuSK identifies tyrosine phosphorylation of Rab GTPases. Mol. Cell. Proteom. 21, 100221 (2022). · DOI
  37. Kim, N. et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135, 334–342 (2008). · DOI · Paper page
  38. Lundby, A. et al. Oncogenic mutations rewire signaling pathways by switching protein recruitment to phosphotyrosine sites. Cell 179, 543–560 (2019). · DOI
  39. Reckel, S. et al. Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics. Leukemia 31, 1502–1512 (2017). · DOI
  40. Wagner, S. A., Szczesniak, P. P., Voigt, A., Gräf, J. F. & Beli, P. Proteomic analysis of tyrosine phosphorylation induced by exogenous expression of oncogenic kinase fusions identified in lung adenocarcinoma. Proteomics 21, 2000283 (2021). · DOI
  41. Zingg, D. et al. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 608, 609–617 (2022). · DOI
  42. Ross, K. E. et al. Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer. PLoS Comput. Biol. 19, e1010690 (2023). · DOI
  43. Lombardo, L. J. et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658–6661 (2004). · DOI
  44. Yeh, C.-T. et al. Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma. Oncogenesis 10, 56 (2021).
  45. Booth, L. et al. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget 7, 19620 (2016). · DOI
  46. Sanchez-Vega, F. et al. EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer. Cancer Discov. 9, 199–209 (2019). · DOI
  47. Levinson, N. M., Seeliger, M. A., Cole, P. A. & Kuriyan, J. Structural basis for the recognition of c-Src by its inactivator Csk. Cell 134, 124–134 (2008). · DOI
  48. Fan, J. et al. Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect. J. Biol. Chem. 289, 26533–26541 (2014). · DOI
  49. Songyang, Z. & Cantley, L. C. Recognition and specificity in protein tyrosine kinase-mediated signalling. Trends Biochem. Sci. 20, 470–475 (1995). · DOI
  50. Zhou, S. et al. SH2 domains recognize specific phosphopeptide sequences. Cell 72, 767–778 (1993). · DOI
  51. Li, L. et al. Prediction of phosphotyrosine signaling networks using a scoring matrix-assisted ligand identification approach. Nucleic Acids Res. 36, 3263–3273 (2008). · DOI
  52. Shan, X. & Wange, R. L. Itk/Emt/Tsk activation in response to CD3 cross-linking in Jurkat T cells requires ZAP-70 and Lat and is independent of membrane recruitment. J. Biol. Chem. 274, 29323–29330 (1999). · DOI
  53. Salojin, K. V., Zhang, J., Meagher, C. & Delovitch, T. L. ZAP-70 is essential for the T cell antigen receptor-induced plasma membrane targeting of SOS and Vav in T cells. J. Biol. Chem. 275, 5966–5975 (2000). · DOI
  54. Plowman, G. D., Sudarsanam, S., Bingham, J., Whyte, D. & Hunter, T. The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms. Proc. Natl Acad. Sci. USA 96, 13603–13610 (1999). · DOI
  55. Joughin, B. A., Liu, C., Lauffenburger, D. A., Hogue, C. W. & Yaffe, M. B. Protein kinases display minimal interpositional dependence on substrate sequence: potential implications for the evolution of signalling networks. Philos. Trans. R. Soc. B 367, 2574–2583 (2012). · DOI
  56. Suga, H. & Miller, W. T. Src signaling in a low-complexity unicellular kinome. Sci. Rep. 8, 5362 (2018). · DOI
  57. Miller, M. L. et al. Linear motif atlas for phosphorylation-dependent signaling. Sci. Signal. 1, ra2 (2008). · DOI
  58. Chen, M. J., Dixon, J. E. & Manning, G. Genomics and evolution of protein phosphatases. Sci. Signal. 10, eaag1796 (2017). · DOI
  59. Wynn, R. M., Davie, J. R., Cox, R. P. & Chuang, D. T. Chaperonins groEL and groES promote assembly of heterotetramers (alpha 2 beta 2) of mammalian mitochondrial branched-chain alpha-keto acid decarboxylase in Escherichia coli. J. Biol. Chem. 267, 12400–12403 (1992). · DOI
  60. Song, J.-L., Li, J., Huang, Y.-S. & Chuang, D. T. Encapsulation of an 86-kDa assembly intermediate inside the cavities of GroEL and its single-ring variant SR1 by GroES. J. Biol. Chem. 278, 2515–2521 (2003). · DOI
  61. Park, J. M. et al. The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. PLoS Biol. 19, e3001281 (2021). · DOI
  62. Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, 2016). · DOI
  63. Wagih, O. ggseqlogo: a versatile R package for drawing sequence logos. Bioinformatics 33, 3645–3647 (2017). · DOI
  64. Modi, V. & Dunbrack Jr, R. L. A structurally-validated multiple sequence alignment of 497 human protein kinase domains. Sci. Rep. 9, 19790 (2019).
  65. Metz, K. S. et al. Coral: clear and customizable visualization of human kinome data. Cell Syst. 7, 347–350 (2018). · DOI
  66. Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021). · DOI
  67. Hubbard, S. R., Wei, L. & Hendrickson, W. A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746–754 (1994). · DOI
  68. Glassman, C. R. et al. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science 376, 163–169 (2022). · DOI
  69. Chen, X. et al. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93, 827–839 (1998). · DOI
  70. Endres, N. F. et al. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152, 543–556 (2013). · DOI
  71. Lu, C. et al. Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Mol. Cell. Biol. 30, 5432–5443 (2010). · DOI
  72. Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236–4243 (2002).
  73. Waksman, G. et al. Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature 358, 646–653 (1992). · DOI
  74. Modi, V. & Dunbrack Jr, R. L. Kincore: a web resource for structural classification of protein kinases and their inhibitors. Nucleic Acids Res. 50, D654–D664 (2022). · DOI · Paper page

Cited by

Sorted by citations

See all 189

Metadata

Authors
Yaron-Barir, T. M., Joughin, B. A., Huntsman, E. M., Kerelsky, A., Cizin, D. M., Cohen, B. M., Regev, A., Song, J., Vasan, N., Lin, T.-Y., Orozco, J. M., Schoenherr, C., Sagum, C., Bedford, M. T., Wynn, R. M., Tso, S.-C., Chuang, D. T., Li, L., Li, S. S.-C., Creixell, P., Krismer, K., Takegami, M., Lee, H., Zhang, B., Lu, J., Cossentino, I., Landry, S. D., Uduman, M., Blenis, J., Elemento, O., Frame, M. C., Hornbeck, P. V., Cantley, L. C., Turk, B. E., Yaffe, M. B., & Johnson, J. L.
ORCID
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
2024-05-08
Volume
629
Issue
8014
Pages
1174-1181
ISSN
  • 0028-0836
  • 1476-4687
DOI
10.1038/s41586-024-07407-y
PMC
PMC11136658
Cited by
189
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review